BridgeBio Pharma : BBIO – Acoramidis AG10 TTR –

Higher Risk of Mortality in Previously Hospitalized Patients: Insights From ATTRibute-CM


Ahmad Masri1, Michele Emdin2, Keyur Shah3, Kunal Bhatt4,...

Related Keywords

Australia , Portland , Oregon , United States , Dallas , Texas , Brisbane , Queensland , San Francisco , California , Palo Alto , Perth , Western Australia , Stanford University , Italy , Dariusz Korczyk , Kunal Bhatt , Michel Khouri , Kevin Alexander , Jonathanc Fox , Noel Dasgupta , Ahmad Masri , Michele Emdin , Martha Grogan , Michael Johnstone , Suresh Siddhanti , Olakunle Akinboboye , Fondazioneg Monasterio , Mazen Hanna , Leonid Katz , Keyur Shah , , Astrazeneca , University Of Pittsburgh Medical Center , Syneos Health Medical Communications , Steward Health Care , Pfizer , Bridgebio Pharma Inc , Janssen Pharmaceuticals , Virginia Commonwealth University Health , Stanford University School Of Medicine , Shweta Bio Pharma Inc , Indiana University School Of Medicine , Duke Health , Bio Pharma Inc , Novo Nordisk , York Heart Association , Oregon Health Science University , Higher Risk , Previously Hospitalized Patients , Insights From , Kaitlyn Lam , Prem Soman , Science University , Commonwealth University Health , Health Care , University School , Barbara Zucker School , Alexandra Hospital , Australia Advanced Heart Failure , Cardiac Transplant Service , Pittsburgh Medical Center , Bio Pharma , Baseline Characteristics , Meier Curve , Cumulative Events , Bridgebio Pharma , New York Heart Association , Shweta Rane ,